Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glycine receptor activation promotes pancreatic islet cell proliferation via the PI3K/mTORC1/p70S6K pathway
Ziyi Zhang, … , Feihan F. Dai, Michael B. Wheeler
Ziyi Zhang, … , Feihan F. Dai, Michael B. Wheeler
Published April 22, 2025
Citation Information: JCI Insight. 2025;10(8):e178754. https://doi.org/10.1172/jci.insight.178754.
View: Text | PDF
Research Article Endocrinology

Glycine receptor activation promotes pancreatic islet cell proliferation via the PI3K/mTORC1/p70S6K pathway

  • Text
  • PDF
Abstract

Glycine and β-alanine activate glycine receptors (GlyRs), with glycine known to enhance insulin secretion from pancreatic islet β cells, primarily through GlyR activation. However, the effects of GlyR activation on β cell proliferation have not been examined. Here, we aim to investigate the potential proliferative effects of glycine and β-alanine on islets. In vitro experiments on mouse and human islets revealed that glycine and β-alanine, via GlyR activation, stimulated the proliferation of β cells and α cells, without affecting insulin or glucagon secretion. Further analysis indicated the involvement of the PI3K/mTORC1/p70S6K signaling pathway in this process. Inhibition of GlyRs and PI3K/mTORC1/p70S6K signaling attenuated proliferative effects of glycine and β-alanine. In vivo and ex vivo studies supported these findings, showing increased β and α cell mass after 12 weeks of oral administration of glycine and β-alanine, with no changes in insulin secretion or glucose homeostasis under normal conditions. However, during an acute insulin resistance induced by insulin receptor antagonist S961, glycine and β-alanine enhanced insulin secretion and reduced blood glucose levels by increasing β cell secretory capacity. These findings demonstrate glycine and β-alanine in vivo and in vitro promote islet cell proliferation via GlyR activation and the PI3K/mTORC1/p70S6K pathway, potentially providing a target to enhance islet capacity.

Authors

Ziyi Zhang, Wenyue W. Ye, Anthony L. Piro, Dian-Shi Wang, Ashley Untereiner, Sulayman A. Lyons, Alpana Bhattacharjee, Ishnoor Singh, Jacqueline L. Beaudry, Beverley A. Orser, Feihan F. Dai, Michael B. Wheeler

×

Figure 3

Glycine and β-alanine stimulate both β cell and α cell proliferation in human islets via glycine receptor in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Glycine and β-alanine stimulate both β cell and α cell proliferation in ...
(A) Workflow for in vitro treatment of human islets. (B and C) Representative images of Ki67+ cells and islet cell proliferation in human islets treated with vehicle, 1mM glycine, or 1 mM β-alanine for 5 days in vitro. Harmine (10 μM) was used as a positive control for islet cell proliferation. We used 30 islets per donor, with an average of 7,490 cells per sample to derive the data. Cell proliferation was calculated by normalizing Ki67+ β cell/α cell numbers to total β cell/α cell numbers on cytospin slides. Scale bar: 50 μm. White arrows indicate Ki67+ proliferating α cells and β cells. (D) Islet cell proliferative in primary human islets treated with vehicle, 1 mM glycine, or 1 mM β-alanine, with or without 1 μM strychnine for 5 days. Data are depicted as mean ± SEM. Statistical significance was determined by using Mann-Whitney U test or unpaired t test dependent on dataset normality test, with Holm-Bonferroni correction applied for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group. #P < 0.05, compared with the glycine or β-alanine treatment group. STR, strychnine. We used islets from 11 donors, 7 of 11 donors have accessible HbA1c values, all falling within the normal range.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts